The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce a grant to help fund the advancement of biopharmaceutical manufacturing technology in the U.S. and globally from the Bill & Melinda Gates Foundation.
NIIMBL will receive up to $1.5M from the foundation to support the development of innovative technologies to reduce the cost of manufacturing biopharmaceuticals. This grant provides a valuable resource for leading scientists and subject matter experts from the NIIMBL community to develop manufacturing technology solutions that increase speed to market and lower costs for biopharmaceuticals to improve healthcare outcomes for all patients, including those in underserved markets and developing nations, through enhanced access to life-saving medicines and vaccines.
“The innovations needed to address global health needs are well-aligned with the innovations that the NIIMBL community is pursuing. We are incredibly excited to collaborate with the Bill & Melinda Gates Foundation to address society’s need for access to safe, effective, high quality medicines” said Kelvin Lee, NIIMBL Institute Director.
As a result of this grant, the foundation will participate in NIIMBL activities including technology workshops, teaming meetings, technology roadmapping, and committees.
As part of the grant, NIIMBL funds will be awarded through a project call process in which teams comprised of NIIMBL members will propose innovation projects that align with the strategic goals and priority topics articulated by NIIMBL and the foundation. Like other NIIMBL project calls, these teams will offer at least a 1:1 matching commitment from project partners. Project teams are limited to NIIMBL members only.
All NIIMBL projects that are funded by this collaboration will follow the foundation’s Global Access requirements to ensure innovations have a positive impact on the populations that the foundation serves.
